explore -WSS

explore

author：explore 2025-09-27 12:55:26 - browse：71

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： A new House health package & hospitals’ new site

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Readout Newsletter: Illumina, CRISPR, Regeneron

House transparency, PBM reform bill gains bipartisan support

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Stem cell treatment guidelines are released by FDA

Snackable artificial intelligence, expert AI, and the pharma industry

hotspot

explore

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Yancopoulos of Regeneron works to expand Dupixent success

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cancer, immunology, HIV research ensnared in fetal tissue politics

Apple is now the first public company to be valued at $3 trillion

Stem cell treatment guidelines are released by FDA

Jerome Adams on the need for new antivirals for Covid

Pfizer, Moderna say biotech, pharma drug development is a sprint

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Bring on the sabbaticals for nurses

Wikipedia

Amazon on where the company's health care bets are headed next

Yancopoulos of Regeneron works to expand Dupixent success

How generative AI is inspiring dreams of a health data revolution

How to fix cancer clinical trials' diversity problem

Yancopoulos of Regeneron works to expand Dupixent success

House transparency, PBM reform bill gains bipartisan support

explore

entertainment

focus

focus